Sunday 21/December/2025 – 08:35 PM
The Egyptian Medicines Authority decided to withdraw the anti-cough drug Celgon, produced by Epico, from the local market in its two pharmaceutical forms: drops and suppositories, against the backdrop of the decision of the Supreme Technical Committee for Drug Control to cancel and permanently stop the registration of the preparations, an official source in the authority told Cairo 24.
Celgon drops and suppositories have been withdrawn due to the risk of overdose
The source, who requested that his name not be published, explained that the decision includes canceling the registration of the product in the form of drops and suppositories, and stopping its production by the manufacturer, due to the difficulty of controlling the dosage in these two pharmaceutical forms, and the danger they may pose to children if the prescribed dose is exceeded.
He pointed out that increasing the dose by just one drop may lead to serious complications, including the occurrence of convulsive seizures in children, which necessitated the withdrawal decision to be taken in order to preserve the safety of patients.
The source added that Ebeco obtained a deadline to implement the decision issued last October, extending until next January, to complete the withdrawal of the product from the market and stop its production completely.
He stressed that the local market includes multiple, safer drug alternatives for treating coughs in children, stressing that the authority’s decisions primarily aim to enhance the safety of circulated medicines and protect public health.
